{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:15:47Z","timestamp":1783329347885,"version":"3.54.6"},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022244","name":"Baptist Health South Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022244","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA282520"],"award-info":[{"award-number":["R01CA282520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201202","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:45:44Z","timestamp":1777311944000},"page":"201202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Protecting the sugar coat on anti-tumor T cells to conceal destruction by tumor microenvironmental landmines"],"prefix":"10.1016","volume":"34","author":[{"given":"Lee Seng","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-7621","authenticated-orcid":false,"given":"Charles J.","family":"Dimitroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201202_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415554","article-title":"Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy","volume":"23","author":"Lau","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201202_bib2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.immuni.2012.03.004","article-title":"Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer","volume":"36","author":"Rabinovich","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201202_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nri2536","article-title":"Turning \u2018sweet\u2019 on immunity: galectin-glycan interactions in immune tolerance and inflammation","volume":"9","author":"Rabinovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201202_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1766555","article-title":"Glycoengineering CAR-T cells to overcome galectin-3-mediated immunosuppression","volume":"17","author":"Lau","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201202_bib5","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1074\/jbc.R110.191429","article-title":"Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function","volume":"286","author":"Zhuo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201202_bib6","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/0008-5472.CAN-14-2379","article-title":"Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment","volume":"75","author":"Zaynagetdinov","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201202_bib7","article-title":"Enforced E-selectin ligand installation enhances homing and efficacy of adoptively transferred T cells","author":"Hou","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.omton.2026.201202_bib8","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1002\/anie.202005934","article-title":"Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy","volume":"60","author":"Hong","year":"2021","journal-title":"Angew. Chem."},{"key":"10.1016\/j.omton.2026.201202_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/jid.2011.335","article-title":"Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity","volume":"132","author":"Cedeno-Laurent","year":"2012","journal-title":"J. Invest. Dermatol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:24:28Z","timestamp":1783326268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926000780"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201202","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protecting the sugar coat on anti-tumor T cells to conceal destruction by tumor microenvironmental landmines","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201202"}}